AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript February 20, 2024 AbCellera Biologics Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.14. AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]

Related Keywords

Canada ,United Kingdom ,British , ,Most Carbon Productive Companies ,Government Of Canada Strategic Innovation Fund ,Arsenal Bio ,Trianni Mouse ,Strategic Innovation ,Carbon Productive Companies ,Carl Hansen ,Tryn Stimart ,Abcellera ,Abcellera Biologics Inc ,Preclinical Development ,Andrew Booth ,Clinical Development ,